Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu.
School of Pharmacy, Graphic Era Hill University.
Int J Surg. 2024 Apr 1;110(4):2498-2501. doi: 10.1097/JS9.0000000000001070.
The SARS-CoV-2 subvariant BA.2.86 'Pirola', first identified in Denmark in August 2023, has manifested with a significantly mutated spike protein profile, suggesting a heightened ability to evade vaccine-induced and infection-induced antibodies. This article outlines the epidemiological spread, immune response implications, and global responses to BA.2.86. Preliminary observations indicate community transmissions of the subvariant, even among those previously infected or vaccinated. Notably, the BA.2.86 infection has shown a potential to amplify antibody responses. The variant's emergence has evoked memories of the Omicron variant's rise in late 2021, though global immunity levels might modulate the impact of BA.2.86 impact differently. Continuous genomic surveillance, coupled with integrated diagnostic and epidemiological strategies, proves crucial in early detection and management. The emergence of BA.2.86 reaffirms the unpredictable nature of the COVID-19 pandemic, emphasizing the need for ongoing research, adaptability, and global collaboration.
SARS-CoV-2 的亚变体 BA.2.86“Pirola”于 2023 年 8 月在丹麦首次被发现，其刺突蛋白谱发生了明显突变，表明其逃避疫苗诱导和感染诱导抗体的能力增强。本文概述了 BA.2.86 的流行病学传播、免疫反应影响和全球应对措施。初步观察表明，该亚变体甚至在那些以前感染或接种过疫苗的人群中也在社区传播。值得注意的是，该变体感染显示出增强抗体反应的潜力。该变体的出现让人想起 2021 年末奥密克戎变体的兴起，尽管全球免疫水平可能会以不同的方式调节 BA.2.86 影响。持续的基因组监测，加上综合诊断和流行病学策略，对于早期发现和管理至关重要。BA.2.86 的出现再次证实了 COVID-19 大流行的不可预测性，强调了持续研究、适应性和全球合作的必要性。
